US Prescription Drug Prices Record Biggest Annual Drop in More Than 60 Years

Prescription drug prices in the United States have recorded their sharpest annual decline in more than six decades, offering a rare sign of relief for consumers even as broader healthcare costs continue to rise.

Prices for prescription drugs fell 3.1 per cent in the 12 months through July 2026, marking the steepest year-on-year decline since March 1963, according to data from the US Bureau of Labor Statistics.

The decline stands out against the wider healthcare sector, where the cost of medical services continued to increase. The latest figures suggest that medicines have become an unusual bright spot in the US inflation data, even though many Americans continue to face high healthcare expenses.

Several factors appear to be contributing to the decline. The growing availability of generic medicines has increased competition, while lower prices for some GLP-1 weight-loss drugs have also played a role in pulling down the overall cost of prescription medication.

The development has also become politically significant. The Trump administration has pointed to its efforts to negotiate lower drug prices and agreements with pharmaceutical companies as evidence that its policies are working.

However, economists and healthcare experts say it is difficult to attribute the entire decline to any single government policy. Medicare’s drug-price negotiation programme, established under the 2022 Inflation Reduction Act, began producing its first negotiated prices in 2026 and is also expected to influence the cost of some widely used medicines.

The decline does not mean that healthcare has suddenly become cheaper across the board. Overall medical care prices continued to rise, with hospital and other healthcare services remaining significant expenses for American households.

For consumers who depend heavily on prescription medication, however, the latest figures could provide some relief. The drop is particularly notable after years of concerns over the affordability of medicines in the US, where prescription costs have remained a major financial burden for many households.

The figures also come as the US government continues to pursue policies aimed at reducing pharmaceutical costs. The administration has promoted initiatives designed to make medicines more affordable, while Medicare’s expanded negotiating powers are gradually changing how some major drugs are priced.